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Abstract
Background: HPV FOCAL is a randomized trial (ISRCTN79347302, registered 20 Apr 2007) comparing high-risk (hr)
HPV testing vs. liquid-based cytology (LBC) for cervical cancer screening of women aged 25–65. We compared
the Digene Hybrid Capture® 2 High-Risk HPV DNA Test® (HC2) and the Roche cobas® 4800 HPV Test (COBAS) for
primary screening.
Methods: Women (n = 6,172) were screened at baseline by HC2 and COBAS and by LBC 24 months later. We
assessed HPV genotyping and reflex LBC for colposcopy triage of baseline HPV positive women.
Results: Overall HC2/COBAS agreement was 96.1 % (kappa 0.75) and positive agreement was 77.5 %. Baseline CIN2
and CIN3+ rates based on HPV screening were 8.6/1,000 and 6.6/1,000 respectively; 24 month rates were 0.7/1,000
and 0.4/1,000 (LBC screening). HC2 and COBAS were concordant positive for 91 % of round 1 CIN2 and 98 % of
CIN3+. CIN3+ was significantly associated with HPV 16 (Odds Ratio [OR] 5.11; 95 % confidence interval [CI] 2.30,
11.37), but not HPV 18 (OR 2.62; 95 % CI 0.73, 9.49), vs. non-HPV 16/18 HPV at baseline. There was no significant
association between HPV genotype and CIN2. CIN3+ was significantly more likely for high-grade (OR 5.99; 95 % CI
2.53, 14.18), but not low-grade (OR 0.54; 95 % CI 0.20, 1.49), vs. negative LBC. No significant association was
observed between LBC grade and CIN2. HPV 16 and 18 were associated with 33 % of CIN2 and 68 % of CIN3+
identified at baseline.
Conclusions: For hrHPV positive women, abnormal reflex LBC is appropriate for colposcopy triage. In addition,
immediate referral of women with HPV 16/18 and normal cytology may allow for earlier detection of CIN2+
lesions which would not be detected until after follow-up testing.
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Background
Persistent infection with high-risk (hr) human papillo-
mavirus (HPV) genotypes is recognized as the cause of
cervical cancer [1, 2] and many screening programs are
shifting from traditional Pap cytology to hrHPV testing.
Screening for hrHPV has higher sensitivity relative to
the Pap for detection of cervical precancerous lesions [3]
(i.e., cervical intraepithelial neoplasia grade two [CIN2]
or CIN2 and worse [CIN2+]). In addition, hrHPV testing
has a negative predictive value for CIN2+ of greater than
99 %, enabling screening intervals to be extended up to
5 years or longer [4–6]. A number of hrHPV screening
tests are commercially available, many of which incorpor-
ate partial genotyping in addition to generating a qualita-
tive positive/negative result [7]. Since HPV 16 and 18
infections account for at least 70 % of cervical cancers
worldwide [8], specific detection of these two genotypes
provides useful additional information for colposcopy
triage of hrHPV positive women who are more likely to
have or develop pre-cancerous lesions [9, 10].
A challenge is that hrHPV testing identifies women
with both persistent and transient HPV infections, with
most of the latter clearing spontaneously within 2 years
[11]. For that reason it is undesirable to refer all hrHPV
positive women to colposcopy since treatment of lesions
which are likely to spontaneously regress is associated
with increased health system costs, patient anxiety [12]
and the potential for reproductive harms [13, 14]. An ef-
ficient triage mechanism is required so that women at
the highest risk of developing rapidly progressive cer-
vical disease are referred to colposcopy, whereas those at
lower risk could be more closely followed for clearance
of transient infections, with colposcopy referral only for
those hrHPV infections which persist. Several triage ap-
proaches for hrHPV positive women have been assessed,
including reflex cytology [5], p16/Ki67 immunostaining
[15], HPV 16/18 genotyping [9, 10] and the detection of
methylation of HPV and/or human genes [16, 17].
In this study, we compared the performance of the
Digene Hybrid Capture® 2 High-Risk HPV DNA Test®
(HC2) to that of the Roche cobas® 4800 HPV Test
(COBAS) for primary cervical screening within the HPV
FOCAL randomized trial. We assessed CIN outcomes




The HPV FOCAL Trial design has been described previ-
ously [18] (Fig. 1). Briefly, the trial is a three-arm, random-
ized controlled trial (ISRCTN79347302, registered 20 Apr
2007) to establish the efficacy of hrHPV screening (using
Fig. 1 HPV FOCAL Trial Design. Abbreviations: HPV Digene Hybrid Capture® 2 high-risk HPV DNA test®, LBC liquid-based cytology, ASCUS atypical
squamous cells, undetermined significance, ASCH atypical squamous cells, cannot exclude high-grade, LSIL low-grade squamous
intraepithelial lesion
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HC2) with liquid-based cytology (LBC) triage of HC2
positive women (Intervention and Safety Arms) compared
to LBC screening with HC2 triage of atypical squamous
cells of undetermined significance (ASCUS) (Control
Arm) in women aged 25–65 years. The Safety Arm was
included to verify the safety of the Intervention Arm 4 year
screening interval by re-screening baseline HC2 negative
women with LBC at 2 years, comparable to the current
standard of care in British Columbia (BC), conventional
cytology every 2 years. Women in the Safety Arm are the
subjects of the present analysis. At baseline, HC2 positive
women with LBC ≥ASCUS were referred immediately to
colposcopy, whereas those HC2 positive/LBC negative for
intraepithelial lesions or malignancy (NILM) were re-
tested by HC2 and LBC at 12 months. Those persistently
HC2 positive and/or LBC ≥ASCUS were then referred to
colposcopy. Visible lesions were biopsied and if none were
seen, endocervical curettage was performed for histo-
logical analysis. Baseline HC2 negative women, together
with those who cleared hrHPV and were LBC NILM at
12 months, had their Safety Arm exit screen at 24 months.
Round 1 refers to the baseline screen together with the
12-month follow-up and Round 2 refers to the exit screen
at 24 months (Fig. 1).
All trial subjects provided written informed consent
and the study was approved by the University of British
Columbia/BC Cancer Agency Clinical Research Ethics
Board.
Laboratory testing
Cervical specimens collected in PreservCyt® (Hologic
Inc., Bedford MA, USA) by participating family physi-
cians in Metro Vancouver and Greater Victoria BC were
used for both hrHPV testing and LBC. For Safety Arm
enrollment and 12 month follow-up specimens, separate
aliquots for HC2 (6 mL) and COBAS (2 mL) were re-
moved from the PreservCyt® vial prior to any other pro-
cessing. At the 24 month exit screen, aliquots for reflex
HC2 testing were obtained after cytology processing. At
enrollment, all specimens were tested by HC2 (Qiagen,
Gaithersburg MD, USA), COBAS (Roche Molecular Sys-
tems, Pleasanton CA, USA) and the Roche Linear Array
HPV Genotyping Test (LA; Roche Molecular Systems).
HC2 generates a qualitative result for the presence or
absence of one or more of 13 hrHPV genotypes (HPV
16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59 and 68). We used
a relative light unit/cutoff (RLU/CO) ratio of ≥1.0 to in-
dicate a positive HC2 result. Specimens which had no
visible cell pellet at the preparation stage were rejected
as inadequate and reported as HC2 invalid. COBAS gen-
erates individual qualitative results for HPV 16, HPV 18
and a pool of 12 other hr (OHR) HPV genotypes (HPV
31, 33, 35, 45, 51, 52, 56, 58, 59, 66 and 68). LA gener-
ates individual qualitative results for the same 14 hrHPV
genotypes as COBAS together with 23 additional HPV
genotypes which are defined for the purposes of this
study as low-risk (lr) HPV. LA was performed using re-
sidual extracts from COBAS testing. COBAS and LA
were performed blinded at the time of collection and
were not used for subject management. Specimens with
initially invalid COBAS results were re-tested to confirm
the invalid result. LBC slides were prepared and stained
for all subjects at enrollment but were not screened and
interpreted unless the subject was HC2 positive. COBAS
and LA results were unblinded and compared with HC2
after Safety Arm women exited the trial at 2 years. LBC
slides were then screened and interpreted retrospectively
for women with baseline HC2 negative/COBAS positive
and HC2 negative/LA positive results. For the latter
group, specimens positive by LA for at least one hrHPV
genotype were classified as hrHPV positive and those
positive for only lrHPV genotype(s) were classified as
lrHPV positive.
Statistical analysis
Overall agreement, Cohen’s kappa, and positive and nega-
tive agreements with 95 % confidence intervals (CI) were
calculated for enrollment HC2 vs. COBAS results. Positive
agreement was calculated by the formula ppos = (2a)/(N +
a - d) and negative agreement by pneg = (2d)/(N – a + d),
where N is the number tested, a is the number positive by
both tests, and d is the number negative by both tests
[19]. Genotyping agreements (overall and positive) and
Cohen’s kappa with 95 % CI were calculated for COBAS
vs. LA.
CIN diagnoses were obtained from the centralized
provincial cervical screening registry, which includes all
screening and histopathology results for BC women. CIN2
and CIN3+ rates with 95 % CI, stratified by baseline HC2
and COBAS results, per 1,000 women screened were cal-
culated and 95 % CI for rates assumed a Poisson distribu-
tion. Round 1 included CIN lesions identified within
2 years after the colposcopy referral date, which could
have occurred at baseline or after 12 months follow-up,
while round 2 included CIN lesions identified within
2 years of the colposcopy referral date following the exit
screen. If a subject had more than one colposcopic biopsy,
the result for the highest grade CIN lesion identified was
used for analysis. The analyses in this paper were based
only on CIN lesions identified among women referred to
colposcopy as per the FOCAL trial protocol. For trial
quality assurance purposes, periodic audits of the provin-
cial registry were conducted to identify CIN2+ lesions
among trial subjects whose colposcopy referrals were not
based on the trial protocol. Any additional CIN2+ identi-
fied by the audits were not included in the analyses.
A multivariate logistic regression model was fitted to
the data to test the hypothesis regarding the relationship
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between HPV genotype and reflex LBC results and the
likelihood of a CIN outcome. Since a given subject may
be positive for more than one hrHPV genotype, subjects
were classified hierarchically for analysis: for HPV 16, the
subject was HPV 16 positive but could also be positive for
HPV 18 and OHR HPV genotypes; for HPV 18, the sub-
ject was HPV 16 negative, HPV 18 positive, and could also
be positive for OHR HPV genotypes; for OHR HPV, the
subject was negative for HPV 16 and 18 and positive for
one or more of the OHR HPV genotypes.
The Median score and Mann-Whitney U tests were
used to calculate p values for the median HC2 RLU/CO
and COBAS cycle threshold (Ct) values for concordant vs.
discordant hrHPV positive specimens. The significance of
the differences between proportions used a Z score test.
All statistical calculations were performed using SAS v.9.3
(SAS Institute Inc., Cary NC, USA).
Results
HC2 and COBAS positivity rates
Among 6,214 women enrolled to the Safety Arm, 10
(0.16 %) and 11 (0.18 %) respectively had invalid HC2
and COBAS results, and 21 (0.34 %) had one or more
missing HC2, COBAS or LA results. The present analysis
includes the 6,172 (99.3 %) women with valid baseline
HC2, COBAS and LA results. Overall HC2/COBAS agree-
ment was 96.1 % (95 % CI: 95.6 – 96.6) and Cohen’s kappa
was 0.75 (95 % CI: 0.72 – 0.79) (Table 1). Positive and
negative agreements were 77.5 % (95 % CI: 74.7 – 80.3)
and 97.9 % (95 % CI: 97.6 – 98.2) respectively. The re-
spective baseline HC2 and COBAS positivity rates were
8.4 % (516/6,172; 95 % CI: 7.7 – 9.1) and 8.8 % (542/6,172;
95 % CI: 8.1 – 9.5). HC2 positivity rates for those 25–29,
30–34, 35–49 and ≥50 years, were 26.6 % (122/458),
15.1 % (84/556), 7.5 % (213/2,859) and 4.2 % (97/2,299) re-
spectively; the corresponding COBAS rates were 27.9 %
(128/458), 17.4 % (97/556), 7.7 % (219/2,859) and 4.3 %
(98/2,299).
COBAS genotyping
COBAS genotyping demonstrated 2.1 % (128/6,172)
HPV 16 positive, 0.7 % (46/6,171) HPV 18 positive and
7.1 % (437/6,171) OHR HPV positive (Table 2). COBAS
and LA overall genotyping agreements ranged from 97.9
to 99.8 %, positive agreements from 85.7 to 87.0 %, and
the kappa’s (0.85 – 0.87) indicated excellent genotyping
agreement.
HC2 and COBAS result discordance
Discordant HC2/COBAS results were observed among
women of all ages, but were more common among those
25–29 years (34/458; 7.4 %) than those 30 years and
older (204/5,714; 3.6 %; p <0.0001). HC2+/COBAS+
specimens had significantly higher median HC2 RLU/
CO values compared to those HC2+/COBAS– (54.9 vs.
5.9; p <0.0001). Similarly, HC2+/COBAS+ specimens had
significantly lower median COBAS Ct values (30.2 vs.
38.3; p <0.0001) than HC2–/COBAS+ specimens. Median
Ct values were similar when stratified by COBAS genotype
(Table 3). Reflex LBC was abnormal for 36.3 % of those
HC2+/COBAS+, 23.6 % of HC2+/COBAS–, 4.5 % of
HC2–/COBAS+ and 0.5 % of HC2–/COBAS– (Additional
file 1: Table S1).
Correlation of HC2 and COBAS results with linear array
and reflex LBC
LA confirmed hrHPV genotypes in 96.3 % of HC2
+/COBAS+ enrollment specimens (Additional file 1:
Table S1). For those with discordant results, HC2
+/COBAS− were less likely to contain hrHPV genotypes
(12.3 % vs. 68.9 %; p <0.0001) and more likely to contain
only lrHPV genotypes (52.8 % vs. 12.1 %; p <0.0001) than
those HC2−/COBAS+. There was no significant difference
in the overall abnormal reflex LBC proportions for those
with discordant HC2/COBAS results (23.6 % vs. 4.5 %;
p = 0.47), nor for those discordant specimens containing
only lrHPV (26.8 % vs. 18.8 %; p = 0.75). Of interest,
specimens containing multiple hrHPV (43 % vs. 28 %;
Table 1 Digene HC2 and Roche COBAS agreement at baseline
COBAS
All ages Age <30 year Age ≥30 year
Positive Negative Total Positive Negative Total Positive Negative Total
HC2 Positive 410 106 516 108 14 122 302 92 394
Negative 132 5,524 5,656 20 316 336 112 5,208 5,320
Total 542 5,630 6,172 128 330 458 414 5,300 5,714
Overall agreement (95 % CI) 96.1 % (95.6, 96.6) 92.6 % (89.7, 94.7) 96.4 % (95.9, 96.9)
Kappa (95 % CI) 0.75 (0.72, 0.79) 0.81 (0.75, 0.87) 0.73 (0.69, 0.76)
Positive agreement (95 % CI) 77.5 % (74.7, 80.3) 86.4 % (81.9, 90.9) 74.8 % (71.4, 78.1)
Negative agreement (95 % CI) 97.9 % (97.6, 98.2) 94.9 % (93.2, 96.6) 98.1 % (97.8, 98.3)
Abbreviations: HC2 Digene Hybrid Capture® 2 high-risk HPV DNA test®, COBAS Roche cobas® 4800 HPV test, CI confidence interval
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p = 0.002) and lrHPV (42 % vs. 9 %; p = 0.06) genotypes
by LA were more likely to have abnormal LBC com-
pared to those with a single hr- or lrHPV genotype
(Additional file 1: Table S2).
CIN detection
Overall round 1 and 2 CIN2 and CIN3+ rates classified
by HC2 and COBAS results are shown in Table 4. At
round 1, the respective rates were 8.6/1,000 (95 % CI:
6.3 – 10.9) and 6.6/1,000 (95 % CI: 4.6 – 8.7), whereas at
round 2 (LBC screening, with HC2 triage of ASCUS),
the overall rates were 0.7/1,000 (95 % CI: 0.0 – 1.4) and
0.4/1,000 (95 % CI: 0.0 – 0.9) respectively.
Of the round 1 CIN2 and CIN3+, 48/53 (90.6 %)
and 40/41 (97.6 %) respectively were concordant
HC2+/COBAS+. The CIN3 identified among HC2
+/COBAS− discordant subjects was HPV negative by
LA. This subject underwent a loop electrosurgical excision
procedure (LEEP) 1 month following the biopsy, at which
time CIN2 was identified, suggesting that this lesion may
have been destined to regress spontaneously. Immunohis-
tochemistry for p16 was not performed on either the
biopsy or the LEEP specimen. Due to the study blinding, it
was not possible to obtain histopathology at round 1 for
discordant HC2−/COBAS+ subjects, who were not re-
ferred to colposcopy unless they had abnormal LBC at
round 2, 24 months later. At the 24 month exit LBC
screen, among the enrollment HC2−/COBAS+ subjects,
one CIN2 was identified, and at baseline, this subject was
HPV 16 and HPV 51 positive by both COBAS and LA
with NILM LBC. At round 2, LBC had progressed to
high-grade squamous intraepithelial lesion and the subject
was still HPV 16 and HPV 51 positive by both COBAS
and LA. Of the two CIN3 at round 2 among enrollment
HC2−/COBAS− subjects, one was LA HPV 16 and HPV
52 positive at enrollment and HPV 52 positive at exit; the
second was HPV 16 positive at both enrollment and exit.
This suggests that these lesions may have been present at
baseline but were not detected by either HC2 or COBAS.
Of the 94 CIN2+ identified in Round 1, 52 (55 %) had
LBC ≥ASCUS at baseline; of the remaining subjects with
NILM LBC at baseline, 16 (17 %) were HPV 16 or 18
positive. Therefore, if both abnormal LBC and presence
of HPV 16/18 genotypes had been used for colposcopy
referral, 68/94 (72 %) CIN2+ cases would likely have been
identified at the baseline screen, with the remainder identi-
fied when 12 month follow-up testing indicated persistent
non-HPV 16/18 infection.
Regular audits of the provincial registry for CIN2+ le-
sions that were not based on a FOCAL trial colposcopy re-
ferral identified one adenocarcinoma and one endometrial
cancer, both diagnosed ~20 months after the baseline
screens (HC2, COBAS and LA were negative for both
cases). Both subjects underwent hysterectomy and exited
the trial.
HC2 clearance and CIN outcomes
Figure 2 illustrates the round 1 HPV clearance rates and
CIN outcomes for the 516 baseline HC2 positive women.
Of those HC2+/LBC NILM who attended the 12 month
follow-up screen, 177/320 (55.3 %) were persistently HC2
positive, among whom 26/53 (49.1 %) of the round 1 CIN2
and 16/41 (39.0 %) of the round 1 CIN3+ were identified.
LBC progression from NILM at baseline to ≥ASCUS at
12 months was not associated with a higher likelihood of
having CIN2+ vs. those without LBC progression. There
was no CIN2+ among the 143 women who cleared their
hrHPV infections by 12 months.
Colposcopy triage by reflex LBC and HPV genotyping
Since HC2−/COBAS+ women were not referred to col-
poscopy at round 1, assessment of the contributions of
HPV genotype and reflex LBC to CIN2 and CIN3+ out-
comes was performed only for HC2+/COBAS+ subjects
(n = 410). For CIN2, by COBAS, 11/48 (23 %) were HPV
16 positive; 7/48 (15 %) were HPV 18 positive; and 32/
48 (67 %) were positive only for non-HPV 16/18 OHR
HPV. For CIN2, there were no significant differences
based on HPV genotype (p = 0.60) (Table 5). For CIN3+,
23/40 (58 %) were HPV 16 positive, 6/40 (15 %) were
HPV 18 positive and 13/40 (33 %) were positive only for
non-HPV 16/18 OHR HPV. HPV 16 positive subjects
were significantly more likely to have CIN3+ compared
to those positive for non-HPV 16 genotypes (odds ratio
[OR] 5.11, 95 % CI 2.30, 11.37; p = 0.0003), but there
was no significant difference for HPV 18 positive vs.
Table 3 RLU/CO and Ct values for concordant and discordant digene HC2 and Roche COBAS results
RLU/CO Ct (all) Ct (HPV 16 only) Ct (HPV 18 only) Ct (OHR only)
Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3)
HC2+/COBAS+ 54.9 (8.6, 368.4) 30.2 (26.6, 34.2) 29.4 (26.6, 34.2) 30.7 (27.2, 35.0) 30.3 (26.3, 33.8)
HC2+/COBAS− 5.9 (2.7, 16.4) – – – –
HC2−/COBAS+ 0.3 (0.2, 0.5) 38.3 (36.8, 39.1) 39.0 (38.0, 40.0) 38.1 (37.0, 38.8) 38.2 (36.7, 38.9)
HC2−/COBAS− 0.1 (0.1, 0.2) – – – –
Abbreviations: HC2 Digene Hybrid Capture® 2 high-risk HPV DNA test®, COBAS Roche cobas® 4800 HPV test, RLU/CO relative light unit/cutoff, Ct cycle threshold,
Q1 first quartile, Q3 third quartile
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non-HPV 16/18 OHR positive subjects (OR 2.62; 95 %
CI 0.73, 9.49). HPV 16 positive subjects had a higher
proportion of CIN3+ (58 % [23/41]) vs. 23 % [11/48] for
CIN2), whereas the proportions were the same for HPV
18 (15 % [7/48] vs. 15 % [6/40]). Conversely, subjects
positive only for non-HPV 16/18 OHR HPV had a higher
CIN2 proportion compared to CIN3+ (67 % [32/48] vs.
33 % [13/40]).
For reflex LBC, those with high-grade vs. NILM LBC
were significantly more likely to have CIN3+ (OR 5.99,




















Pos/Pos UNSAT 1 1/1 UNSAT 1 0/0
NILM 260 152/143 22 16 NILM 208 0/0
ASCUS 35 35/33 6 2 ASCUS 4 3/3
LSIL 68 68/63 9 4 LSIL 6 6/6
ASCH 18 18/15 4 5 ASCH 2 2/2
HSIL 28 28/25 7 13 HSIL 1 1/1
Total 410 302/280 48 7.8 (5.6 – 10.0) 40 6.5 (4.5 – 8.5) Total 222 13/13 0 – 0 –
Pos/Neg UNSAT 0 0/0 UNSAT 1 0/0
NILM 81 27/23 4 NILM 75 0/0
ASCUS 10 10/9 1 ASCUS 2 1/1
LSIL 13 13/12 LSIL 4 4/4
ASCH 2 2/2 1 ASCH 0 0/0
HSIL 0 0/0 HSIL 0 0/0
Total 106 52/46 5b 0.8 (0.1 – 1.5) 1c 0.2 (0.0 – 0.5) Total 82 5/5 0 – 0 –
Neg/Pos UNSAT 3 UNSAT 1 0/0
NILM 123 NILM 117 0/0
ASCUS 1 ASCUS 0 0/0
LSIL 5 LSIL 2 2/2
ASCH 0 ASCH 0 0/0
HSIL 0 HSIL 1 1/1 1
Total 132 Total 121 3/3 1d 0.2 (0.0 – 0.5) 0 -
Neg/Neg UNSAT 12 UNSAT 24 6/5
Not done 4901
NILM 585 NILM 4957 1/0






LSIL 8 LSIL 38 38/36 2
ASCH 1 ASCH 4 4/4
HSIL 0 HSIL 5 5/5 1 2
Total 5524 Total 5065 62/58 3e 0.6 (0.0 – 1.3) 2f 0.4 (0.0 – 0.9)
Total 6172 354/326 53 8.6 (6.3 – 10.9) 41 6.6 (4.6 – 8.7) Total 5490 83/79 4 0.7 (0.0 – 1.4) 2 0.4 (0.0 – 0.9)
aRate per 1,000 women screened. bBy Linear Array, two were HPV 52 positive, one HPV 56 positive, one HPV 66 positive and one HPV negative. cLinear Array was
HPV negative; a LEEP one month later showed CIN2. dLinear Array was HPV 16 and HPV 51 positive at both baseline and 24 months. eBy Linear Array, two were
HPV negative at baseline; at 24 months one was HPV 66 positive and the second was HPV 35 and HPV 58 positive. The third case was HPV 66 positive at baseline
and HPV 16, HPV 18 and HPV 66 positive at 24 months. fBy Linear Array, one was HPV 16 and HPV 52 positive at baseline and HPV 52 positive at 24 months; the
second was HPV 16 positive at both baseline and 24 months
Abbreviations: HC2 Digene Hybrid Capture® 2 high-risk HPV DNA test®, COBAS Roche cobas® 4800 HPV test, UNSAT smear unsatisfactory; NILM negative for intraepithelial
lesions and malignancy, ASCUS atypical squamous cells undetermined significance, ASCH atypical squamous cells, cannot rule out high-grade, LSIL low-grade squamous
intraepithelial lesion, HSIL high-grade squamous intraepithelial lesion, CIN cervical intraepithelial neoplasia, LEEP loop electrosurgical excision procedure
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95 % CI 2.53, 14.18; p <0.0001) compared to those with
low-grade vs. NILM LBC. In contrast, there was no
significant difference for CIN2 for those with either
high-grade or low-grade vs. NILM LBC (p = 0.15). There
were no significant interactions between HPV genotype
and LBC (data not shown).
Discussion
In this sub-study of the HPV FOCALTrial Safety Arm, we
demonstrated that over a 2 year screening interval with
hrHPV screening at baseline followed by LBC screening at
24 months, hrHPV testing at baseline identified 94 % of
the CIN2+ lesions detected over the two screening rounds.
Very low CIN2+ rates were observed at the exit LBC
screen, which supports the safety of hrHPV vs. LBC
screening every 2 years. It is important to note that in this
study women were managed only on their HC2 and corre-
sponding cytology results (COBAS results were blinded).
Despite the occurrence of discordant baseline HC2 and











































Fig. 2 Round 1 CIN Outcomes and HPV Clearance Rates for Baseline Digene HC2 Positive Subjects. Abbreviations: HC2 Digene Hybrid Capture® 2
high-risk HPV DNA test®, LBC liquid-based cytology, ASCUS atypical squamous cells, undetermined significance, NILM negative for intraepithelial
lesions and malignancy
Table 5 Multivariate analysis for association of HPV genotype and reflex LBC with CIN2 and CIN3+
CIN2 CIN3+
p value Odds ratio (95 % CI) p value Odds ratio (95 % CI)
HPV genotype 0.60 0.0003
16 vs. non-16 OHR 0.71 (0.33, 1.53) 5.11 (2.30, 11.37)
18 vs. non-16/18 OHR 1.21 (0.42, 3.50) 2.62 (0.73, 9.49)
Reflex LBC 0.15 <0.0001
High-gradea vs. NILM 2.23 (0.96, 5.17) 5.99 (2.53, 14.18)
Low-gradeb vs. NILM 1.02 (0.50, 2.08) 0.54 (0.20, 1.49)
aHigh-grade = ASCH + HSIL. bLow-grade = ASCUS + LSIL
Abbreviations: OHR other high-risk HPV, LBC liquid-based cytology, NILM negative for intraepithelial lesions and malignancy, CIN cervical intraepithelial neoplasia,
ASCUS atypical squamous cells undetermined significance, ASCH atypical squamous cells, cannot rule out high-grade; LSIL low-grade squamous intraepithelial
lesion, HSIL high-grade squamous intraepithelial lesion
Bolded type indicates statistically significant results
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who were both HC2 and COBAS positive. If women had
been managed on both HC2 and COBAS results, it is pos-
sible that additional CIN lesions might have been
identified at baseline among those HC2−/COBAS+. In
agreement with our findings, a comparison study by
Cuzick et al. [7] of the performance of six HPV assays
in a population referred to colposcopy on the basis of
abnormal cytology, showed that both HC2 and COBAS
were positive for all CIN3+ cases. However, in that study
HPV positive/cytology normal women, among whom
greater discordance between various HPV assays and CIN
detection might be expected, were not referred to colpos-
copy. The full impact of discordant HPV results among
cytologically normal women remains under investigation.
It is not unexpected that a given hrHPV assay may miss a
potentially significant CIN, as other trials, including ALTS,
ARTISTIC and POBASCAM, noted that a proportion of
CIN2+ test negative for hrHPV [20–22]. Of note, co-
testing would have identified the CIN3+ that was not
detected by COBAS at baseline, since the LBC result was
atypical squamous cells, cannot rule out high-grade, which
would have resulted in a colposcopy referral. Some studies
have shown that co-testing has a higher sensitivity for
CIN2+ than hrHPV screening alone [23, 24], whereas
others have not demonstrated a difference [25, 26].
The round 1 CIN2 and CIN3+ rates based on primary
hrHPV screening (8.6/1,000 and 6.6/1,000 respectively)
were higher than in the HPV FOCAL Control Arm
(LBC screening, with HC2 triage of ASCUS) which had
round 1 rates of 6.0/1,000 and 5.0/1,000 respectively
[27]. The CIN2+ rate in this study (15.2/1,000) was also
higher than the 2011 CIN2+ rate of 6.3/1,000 for women
aged 20–69 in the BC provincial cervical screening pro-
gram (using conventional cytology) [28]. The round 1
CIN rates in our study are similar to the verification
bias-adjusted rates in the ATHENA trial (CIN2: 8.6 vs.
8.0; CIN3+: 6.6 vs. 10.0) [29]. The FOCAL trial did not
adjust for verification bias, but there are some differences
in the study populations, e.g., the mean age of FOCAL vs.
ATHENA subjects (46 vs. 40 years) and those who
ever smoked (36.4 % vs. 29.3 %). The FOCAL trial had
a higher proportion of individuals with Asian ethnic
background (12.5 % vs. 1.6 %), whereas ATHENA had
a higher proportion of Black/African American individuals
(14.0 %) compared to FOCAL (3.3 %, which includes
Aboriginals) [27, 29].
While our study had a lower COBAS positivity rate
than ATHENA (8.8 % vs. 12.6 %) [29], in both studies
HPV 16 (2.1 % vs. 2.8 %) was approximately three times
more commonly detected than HPV 18 (0.7 % vs. 1.0 %).
These data are consistent with other studies [7], including a
recent BC population-based HPV prevalence survey among
unvaccinated women aged 15–69 years attending cervical
screening (HPV 16: 2.7 %; HPV 18: 1.1 %, using LA) [30].
Our study identified similar HPV 16- but higher HPV
18-attributable CIN2 and CIN3+ proportions compared
to ATHENA. We identified HPV 16 in 23 % (11/48) of
CIN2 vs. 30 % (57/192) for ATHENA, and 58 % (23/40)
vs. 50 % (153/305) for CIN3+. We identified HPV 18 in
15 % (7/40) of CIN2 compared to 3 % (6/192) for
ATHENA, and 15 % (6/40) vs. 8 % (25/305) for CIN3+.
For concordant HC2/COBAS positive subjects, CIN3+
was significantly more likely when LBC was high-grade
vs. NILM. Reflex LBC dysplasia was not significantly dif-
ferent for CIN2. CIN3+ was significantly more likely for
HPV 16 vs. non-HPV 16 HPV positive subjects, while
no significant differences in CIN3+ were found for HPV
18 vs. non-HPV 16/18 OHR genotypes. There was no
significant difference between the CIN2-associated HPV
genotypes. These findings are in agreement with the
ATHENA trial which concluded that a combination of
HPV 16/18 genotyping and reflex cytology is a suitable
triage strategy for hrHPV positive women [26].
Specimens with discordant HC2/COBAS results had
RLU/CO ratios and Ct values significantly closer to the
test limits of detection than concordant positive speci-
mens. It seems reasonable that specimens likely to have
lower viral loads (based on low RLU/CO ratios or high
Ct values) would be more likely to produce discordant
results with different assays. Furthermore, some of these
discordant results likely reflect false-positives [31], which
are less likely to be consistent between assays. This is
supported by the lower CIN2+ rates among women with
HC2+/COBAS− results.
Our finding that 45 % of HC2 positive women with
NILM LBC at baseline cleared their hrHPV infections
after 12 months is consistent with the published literature
[11, 32, 33]. The high rate of HPV clearance supports
recommendations that when LBC is used for triage, an
appropriate way to manage hrHPV positive women
with NILM cytology is by re-testing for HPV clearance
after a short follow-up period, e.g., 12–18 months [33, 34].
However, this may result in a high rate of loss to follow-up
of these women, some of whom will have underlying
CIN2+ [9, 20, 26]. A triage test which efficiently identifies
a high likelihood of CIN2+ at the time of the initial posi-
tive HPV screen test would be of considerable benefit.
Specimens containing only lrHPV types frequently had
low-grade LBC abnormalities [11 % (57/516) of HC2
and 3 % (17/542) of COBAS positive results] which may
have implications for selection of a primary HPV screen-
ing assay if LBC is to be used for triage. Since lrHPV’s
have a negligible association with CIN2+ [35], these in-
dividuals would not benefit from colposcopy referral.
Full genotyping of all hrHPV positives will become in-
creasingly feasible with the availability of automated
commercial genotyping assays and this information could
be used to prioritize women for colposcopy. However, cost
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considerations may preclude its use to help identify
women with false positive hrHPV screening results. This
emphasizes the need for better triage tests to avoid colpos-
copy over-referral and the associated potential harms.
An important limitation of this study was the inability
to obtain CIN outcomes at round 1 for women with
HC2−/COBAS+ discordant results, since baseline COBAS
results were blinded until after study exit. This precluded
comparison of the sensitivity and specificity of the HC2 and
COBAS assays. In addition, had these women been referred
to colposcopy at baseline, it is possible that additional CIN
lesions would have been detected, as was observed for the
HC2+/COBAS− group. Furthermore, no hrHPV testing
was performed at the 24 month study exit except for HC2
triage of women with ASCUS LBC. Although one CIN2
was identified at round 2 among baseline HC2−/COBAS+
women, it is possible that the use of only LBC at round 2
was not sufficiently sensitive to demonstrate whether this
group of women had underlying CIN lesions not detected
by HC2 at baseline. A future analysis of the FOCAL Inter-
vention Arm where women were screened with HC2 and
COBAS at both enrollment and the 48 month exit screen
may provide further insight. However, Intervention Arm
COBAS enrollment results were also blinded and not used
for subject management, but both HC2 and COBAS were
used for colposcopy referral at the 48 month exit screen.
Furthermore, there is an opportunity to follow these
women for significant CIN outcomes over longer time
periods once they exit the trial and return to the centralized
cervical screening program. Long term follow-up of Swe-
descreen subjects after a baseline hrHPV positive screen
showed that incidence rate ratios for CIN2+ remained high
for greater than nine years [36], especially for those with
HPV 16, 18, 31 and 33 identified at baseline.
Another limitation relates to the retrospective cytology
interpretations. Reflex LBC for HC2 positive women was
performed as it would be in a real setting, whereas LBC
slides for HC2 negative, COBAS and/or LA positive
women were examined approximately two years later.
This could have biased the LBC interpretations relative
to those conducted in real-time.
Conclusions
This study demonstrated that over a 2 year screening
interval with hrHPV testing at baseline, followed by LBC
screening at 24 months, 94 % of CIN2+ detected over
the two screening rounds were hrHPV positive at base-
line. Women were managed at round 1 only on their
HC2 and corresponding LBC results, but 43/44 CIN3+
were detected among those HC2+/COBAS+. It is pos-
sible that additional CIN cases would have been detected
among HC2−/COBAS+ subjects if COBAS results had
also been used for subject management. Of the CIN2+
identified in Round 1, 55 % had abnormal cytology and
an additional 17 % were HPV 16 or 18 positive at baseline,
demonstrating the added benefit of immediate referral of
women with these genotypes to potentially identify CIN2+
earlier than by follow-up testing of those with NILM
cytology. Therefore, the results of this study support
the use of reflex LBC together with HPV16/18 genotyp-
ing for colposcopy triage of hrHPV positive women.
However, as the cohort of HPV vaccinated women
reaches cervical screening age, the benefits of HPV 16/
18 genotyping for triage will be diminished.
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